key: cord-0789509-o8j17zzs
authors: Zhang, Qi; Wang, Yakun; Qi, Changsong; Shen, Lin; Li, Jian
title: Clinical trial analysis of 2019‐nCoV therapy registered in China
date: 2020-03-05
journal: J Med Virol
DOI: 10.1002/jmv.25733
sha: ef799e1edb74c782c0ae8d387eff62a3f323933e
doc_id: 789509
cord_uid: o8j17zzs

So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period.

Since the outbreak of the novel coronavirus (2019-nCoV), also known as novel coronary pneumonia (NCP) in January 2020, a number of clinical trials for treatment have been registered in China.

Although the time span of study registration was less than 2 weeks (30 January 2020 to 12 February 2020), subtle changes in the classification of registered trials could be seen from the development of the epidemic, including that the proportion of studies targeting critically ill patients had gradually increased in the latter period, and patients' physical and psychological rehabilitation had also received attention. Based on the current registered trials, together with the epidemic situation in China and published literatures of 2019-nCoV, we made a preliminary assessment on the prospects of therapy for 2019-nCoV and the availability of drugs in the short term. 

The experimental drugs included Western medicine, including antiviral drugs, antimalarial drugs, and biotherapy (interferon, stem cell therapy, and immune regulation therapy, etc), and traditional Chinese medicine, and studies of glucocorticoids and plasma also accounted for small proportion ( Figure 2 and Table 1 ). The number of trials on traditional Chinese medicine was much higher than that of the treatment of previous diseases, which meant that The studies for the effects of plasma from recovered patients are ongoing, which is promising. Besides, vaccines are an effective way to prevent and reduce the harm of viruses, 7 

Most of the trials will continue over a period of about 1 year (Table 1) , which means that the results of these studies are likely to be of limited help in the current epidemic, with more value for prevention and treatment in the future. However, the epidemic situation is urgent and the number of patients is huge with a certain critically ill proportion. Therefore, the availability of effective experimental drugs in the short-term may be the most concerned. According to the retrieved data, more than 20 studies would be completed within 6 months, and some important drugs like remdesivir, ASC09, lopinavir, ritonavir, chloroquine, and glucocorticoids might be completed within 4 months.

The RCT of remdesivir for severe NCP and the mild to moderate NCP carried out by China-Japan Friendship Hospital respectively, were expected to be completed by the end of April or early May 2020 (Table 1) (Table 1) . And the studies were expected to be completed by 03 June 2020 and 31 May 2020, respectively. Although the epidemic may be coming to an end at that time, the drugs could be approved for treatment in advance with the preliminary effective results of the interim research (optimistic forecast by March 2020). At the same time, researchers have also carried out the trials for traditional Chinese medicine with a short study period, which might also provide preliminary efficacy and safety data and provide important options for clinical treatment.

Besides, it has been reported that remdesivir, chloroquine phosphate, and farpiravir showed preliminary efficacy in clinical studies, 9 which is encouraging for medical staff and patients who are still in the critical stage of the epidemic. We support that improvement of clinical symptoms and prognosis of disease should be used as the most important indicators to evaluate the short-term efficacy of experimental drugs. And once supported by interim research data, the drugs should be applied early.

Besides, the current severe illness rate is estimated to be about 15%. It is unclear whether some of these patients will have long-term recovery problems such as impaired lung function or other organ dysfunction, which should be paid attention to and the study should be initiated to confirm.

To carry out a large number of clinical trials so rapidly is also worrying. Due to the urgency, the theoretical bases of some trials were needed to be discussed more comprehensively, and the designs might not be reasonable enough. Whether these factors will increase the risk of the patients is also a matter which should be treated with caution in the research.

Compared with the SARS epidemic period 17 years ago, China had a stronger ability to conduct new drug clinical trials independently in an emergency event. However, there is still no effective therapy for virus infection. When expecting that these studies can provide effective treatment for NCP in China, we need to carry out these trials carefully to ensure the safety of the patients.

CT imaging features of 2019 novel coronavirus (2019-nCoV)

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

SARS: systematic review of treatment effects

High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses

Can an anti-HIV combination or other existing drugs outwit the new coronavirus? Science

Scientists are moving at record speed to create new coronavirus vaccines-But they may come too late

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

First case of 2019 novel coronavirus in the United States

Clinical trial analysis of 2019-nCoV therapy registered in China

The authors declare that there are no conflict of interests.

http://orcid.org/0000-0002-8144-3609Yakun Wang http://orcid.org/0000-0001-5579-2998Jian Li http://orcid.org/0000-0002-9333-3255